Plerixafor

CHEMBL18442 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
502.8 g/mol
LogP
Phase
4

Plerixafor is a bicyclam CXCR4 chemokine receptor antagonist that blocks the interaction between CXCR4 and its ligand CXCL12/SDF-1, thereby mobilizing hematopoietic stem and progenitor cells from the bone marrow into the peripheral blood. It is used in combination with granulocyte colony-stimulating factor (G-CSF) to enhance stem cell mobilization prior to autologous stem cell transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

น้ำหนักโมเลกุล

502.8000 g/mol

LogP

0.00

TPSA

78.70 Ų

Lipinski RO5

ไม่ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1

InChI

InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2

Molecular Formula

C28H54N8

HBD / HBA

6 / 8

พันธะที่หมุนได้

4

อะตอมหนัก

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Plerixafor is a bicyclam CXCR4 chemokine receptor antagonist that blocks the interaction between CXCR4 and its ligand CXCL12/SDF-1, thereby mobilizing hematopoietic stem and progenitor cells from the bone marrow into the peripheral blood. It is used in combination with granulocyte colony-stimulating factor (G-CSF) to enhance stem cell mobilization prior to autologous stem cell transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Yes, Plerixafor is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL18442. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 65015. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.